MWM
EW icon

Meridian Wealth Management’s Edwards Lifesciences EW Stock Holding History

Meridian Wealth Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Buy
+2,900
New +$239K 0.01% 718

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Meridian Wealth Management's EW Position: Q1 2026 in Review

Meridian Wealth Management reduced its Edwards Lifesciences (EW) stake by 7.3% in Q1 2026, selling an estimated $30K and leaving 4,648 shares worth $372K. The position accounts for 0.01% of the portfolio, ranked #598.

Meridian Wealth Management first reported a position in EW in Q3 2018 and has held it in 25 quarters since. The position peaked at $1.49M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Meridian Wealth Management held 4,648 shares of Edwards Lifesciences worth $372K as of Q1 2026.
  • Meridian Wealth Management sold 364 Edwards Lifesciences shares in Q1 2026, an estimated $30K.
  • Edwards Lifesciences made up 0.01% of Meridian Wealth Management's portfolio in Q1 2026, its #598 holding.
  • Meridian Wealth Management first reported a position in Edwards Lifesciences in Q3 2018 and has held it in 25 quarters since.
  • Meridian Wealth Management's Edwards Lifesciences position peaked at $1.49M in Q4 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Meridian Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.